Moreover, loss of HPK1 kinase function in preclinical models of cancer results in enhanced anti-tumor T cell activity, suggesting HPK1 attenuates T cell functional responses [6, 15, 16]. The gene discussed is MAP4K1; the disease is neoplasm.